ASLAN Pharmaceuticals (ASLAN; ticker: 6497), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it has received approval from the Board of Taipei Exchange (“TPEx”) to list on TPEx.
ASLAN applied for the listing with Qualified Technology Enterprise (QTE) status with a paid-in capital of NT$1,157 million (US$36.5 million).
Dr Carl Firth is Chairman of ASLAN Pharmaceuticals. The Company is represented by legal firm K&L Gates, and has appointed KGI Securities as the lead underwriter
About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types.
Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform that reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes.
The Company is developing 5 drugs addressing multiple indications including biliary tract cancer, gastric cancer and breast cancer. ASLAN has several compounds in late stage development: varlitnib (ASLAN001), a pan-HER inhibitor which has completed phase 2 studies in gastric and breast cancer, and is entering pivotal studies for biliary tract cancer; and ASLAN002 (partnered with BMS), a RON and cMET inhibitor in phase 2 development for gastric and breast cancer.